ClinicalTrials.gg
SuspendedNCT02853578LaennecUpdated Jul 8, 2019

Busonid® (Budesonide 200 mcg and 400 mcg) to Treat Asthma Not Controlled or Partially Controlled

A Phase 3 interventional study of Busonid (budesonide 200mcg and 400mcg) in Asthma, sponsored by Ache Laboratorios Farmaceuticos S.A.. Suspended at 5 sites in Brazil. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-07-08.

Sponsored by Ache Laboratorios Farmaceuticos S.A. · Phase 3, Interventional, and Treatment

Why this study was suspended
The viability of the study is being analyzed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Planned enrollment
70th of 108
80 · median 124
Started
2019
with 1 other
Phase 3
51 of 110
3 open now
Registered
87th of 110
by date

Among the 110 studies testing budesonide in Asthma, this one is the 70th largest by planned enrollment of the 108 interventional ones that give a count, is one of 2 that started in 2019, is one of 51 in phase 3, and was the 87th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

National clinical trial, phase III, multicenter, single-arm, efficacy study, 80 participants of both sexes, aged equal or more than 12 and less than 65 years. The group will use Busonid® (budesonide 200mcg and 400mcg) one application (inhalation) of 200 mcg every 12 hours (400mcg / day). During follow-up visits if the participant has not shown an increase in forced expiratory volume in one second greater than 12% and greater than 0,20L or 200ml in spirometry compared with baseline visit, will increase the dose to 800 mcg / day (2x 400 mcg day).

The study aims to revalidate by the National Health Surveillance Agency (ANVISA) the registration of the drug Busonid® which there is a vast scientific literature on the pre-clinical and clinical evidence that the efficacy and safety of budesonide. Thus, outlined is a single-arm study, which is applied to the study of the group of participants the same intervention for a certain period and the participants are evaluated for response.

Read the detailed description

Busonid® is composed of budesonide and has two performances of 200mcg and 400mcg. It is a corticosteroid hormone with topical anti-inflammatory activity. The slow and continuous release of budesonide in the airways due to their esterification and their short plasma half life increases the selectivity of the corticosteroid to the airways, in patients with asthma, inhaled corticosteroids have a broad spectrum of anti-inflammatory effects, such as reducing the number of inflammatory cells in the lungs and inhibiting the synthesis and release of cytokines and other inflammatory mediators.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Uncontrolled asthma diagnosis or partially controlled in according to the Guidelines of the Brazilian Society of Pneumology and Phlebology for Asthma Management - 2012;
  • Capacity of survey participants or legal guardians to understand and consent to the participation of the research participant in this clinical study, expressed by signing the form;
  • Ability of children survey participants 18 years understand and nod their participation in this clinical study, manifested by signing the informed assent form;
  • Baseline in screening visit between 55% and 85% of predicted value (before bronchodilator use), including the extremes (ensuring that the lung function test has been performed properly);
  • Increase of 12% and 200 ml of forced expiratory volume in one second after the reversibility test at screening visit / initiation of treatment.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of pneumonia, pneumothorax, pneumomediastinum, , pulmonary tuberculosis, deficiency α1anti antitrypsin, lung mycosis (blastomycosis, histoplasmosis), bronchiectasis, pulmonary cystic fibrosis or other significant respiratory disease, according to the investigator;
  • Pneumothorax history, pulmonary tuberculosis, lung mycosis (blastomycosis, histoplasmosis) and COPD;
  • therapy;
  • Survey participants with immunosuppression of any kind;
  • Thoracic surgery history or any prior neoplastic process of the lung;
  • Significant heart disease;
  • Four or more systemic courses in the last 12 months;
  • Participants who have needed hospitalization or care in the emergency room or emergency service (duration> 12 hours) to airway obstruction control (for exacerbation of asthma), at least once within the last three (03) months;
  • History of asthma crisis with risk of death;
  • Ventilatory support needs due to respiratory failure secondary to asthma within the past five (05) years;
  • Infection of the upper respiratory tract or lower (viral or bacterial) within the last four (04) weeks prior to study entry;
  • Any finding of clinical observation (clinical evaluation / physical) that is interpreted by the medical researcher as a risk to the research participant in the clinical study;
  • Known to drug components used during the study;
  • Use of forbidden drugs in the clinical study described in Protocol;
  • Smokers and former smokers;
  • infection, whether on antiretroviral treatment;
  • History of abuse of illicit drugs;
  • Disorders diagnosis of hypothalamic-pituitary-adrenal axis (hypocortisolism or hypercortisolism);
  • Presence of severe obstruction of lung airflow that may present a risk of death;
  • Women in reproductive age who do not agree to use hormonal or barrier methods of ; except the participants declared that they perform sexual practices or exercise them not to reproductive form;
  • Female participants in a period of pregnancy or breastfeeding;
  • Clinical trial protocols of participation in the last twelve (12) months (CNS Resolution 251 of August 7, 1997, Part III, sub-item J), unless the investigator considers that there may be a direct benefit to it;
  • Family relationship to the second degree or bond with employees or employees of Sponsor and Research Center.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Busonid (budesonide 200mcg and 400mcg)

    It´s a capsule with inhalatoin powder composed of budesonide 200mcg or 400mcg. The experimental drug will be dispensed in a cartridge containing 60 capsules of 200 mcg or 400 mcg and an inhaler. It should be stored at room temperature (between 15 and 30°C) and protected from moisture. Regarding the dosage, the 80 study participants will perform an inhalation 200mcg every 12 hours (400 mcg / day). During follow-up visits (V1 and V2) the attending physician will assess the need for increased PSI dose to 400 mcg every 12 hours (800mcg / day). Study participants should rinse the mouth with water and / or brush your teeth immediately after use of the drug. The duration of treatment may be 12 weeks.

    Drug: Busonid (budesonide 200mcg and 400mcg)

Interventions

  • DrugBusonid (budesonide 200mcg and 400mcg)

    Drug page: Budesonide

    cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler; 1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks.

    Also known as: Busonid

06

What researchers measure

Primary outcomes

  1. Efficacy of Busonid® (budesonide 200 mcg and 400 mcg) in the treatment of asthma after the initiation of treatment (FEV1)

    The absolute change in forced expiratory volume in one second \[FEV1 (L)\], 12 weeks after start of treatment (VF) compared to baseline (V0) was measured by spirometry test.

    Time frame: 12 weeks

Secondary outcomes

  1. Evaluate the FEV1 (L) during treatment compared to baseline.

    Absolute change of FEV1 (L) during treatment (weeks 4, 8 and 12) compared to baseline (week 0).

    Time frame: 4, 8 and 12 weeks

  2. Evaluate the FEV1 (% of predicted) during treatment compared to baseline.

    Absolute change of FEV1 (% of predicted) during treatment (weeks 4, 8 and 12) compared to baseline (week 0).

    Time frame: 4, 8 and 12 weeks

  3. Evaluate the FEV1 / FVC during treatment compared to baseline.

    Absolute change of FEV1 / FVC during treatment (weeks 4, 8 and 12) compared to baseline (week 0).

    Time frame: 4, 8 and 12 weeks

  4. Evaluate the peak expiratory flow behavior measured each morning and evening throughout the treatment as compared to baseline.

    Absolute variation in peak expiratory flow, measured in the morning and evening, through the peak expiratory flow meter laptop at weeks 2, 4, 6, 8, 10 and 12 relative to baseline morning and evening, which will be measured on the day of V0. The peak expiratory flow of weeks 2, 4, 6, 8, 10 and 12 will be determined by the arithmetic mean of the last seven days prior to the week in review.

    Time frame: 2, 4, 6, 8, 10 and 12 weeks

  5. Evaluate the occurrence of nighttime awakenings due to symptoms asthma during treatment.

    Nights rate with awakenings due to asthma symptoms, set at 2-week intervals (1 and 2; 3 and 4; 5 and 6; 7 and 8; 9 and 10; 11 and 12), as assessed by daily participant.

    Time frame: 12 weeks

  6. Assess the need for use of rescue medication over treatment.

    Average number of rescue medication used by jets day set at 2 week intervals (1 and 2; 3 and 4; 5 and 6; 7 and 8; 9 and 10; 11 and 12) as daily participant.

    Time frame: 12 weeks

  7. Assess satisfaction to treatment by the investigator and participant search / legal representative throughout the treatment.

    Satisfaction with treatment, according to investigator assessment and the research participant / legal representative, expressed by the Visual Analogue Scale.

    Time frame: 4, 8 and 12 weeks

07

Study locations

5 sites
  • Centro de Estudos Multidisciplinar CEPES da Faculdade de Medicina do ABC
    Santo André, São Paulo, Brazil
  • Centro de Pesquisa do Hospital Nipo Brasileiro
    São Paulo, Brazil
  • Centro de Pesquisa em Pneumologia da Santa Casa de São Paulo
    São Paulo, Brazil
  • Centro Paulista de Investigação Clínica - CEPIC
    São Paulo, Brazil
  • IMA Brasil - Instituto de Medicina Avançada
    São Paulo, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2019; primary completion for Oct 2020, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2016
First posted
Aug 3, 2016
StartEst.
Dec 2019
Primary completionEst.
Oct 2020
CompletionEst.
Dec 2020
Last update
Jul 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02853578
Responsible party
Sponsor
First posted
Aug 3, 2016
Start date
Dec 2019 (estimated)
Primary completion
Oct 2020 (estimated)
Completion
Dec 2020 (estimated)
Last update
Jul 8, 2019

Study contacts

Elie Fiss
principal investigator · Multidisciplinary Studies Center CEPES of the ABC Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion